## Notice of Allowability

Application No. 09/669,301

Applicant(s)

Kudlicki

Examiner

Arun Chakrabarti

Art Unit 1634



The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAII (or previously mailed), a Notice of Allowance (PTOL-85) or other appropria THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. the initiative of the Office or upon petition by the applicant. See 37 CFR	ate communication will be mailed in due course.  This application is subject to withdrawal from issue at	
1. X This communication is responsive to 12/9/02		
2. X The allowed claim(s) is/are 1-7, 9-16, 18-21, 23, 37-49, and 5	51-66	
3.   The drawings filed on are accepted by t		
4. Acknowledgement is made of a claim for foreign priority under	r 35 U.S.C. § 119(a)-(d).	
a) $\square$ All b) $\square$ Some* c) $\square$ None of the:		
1.   Certified copies of the priority documents have been received.	eived.	
2.   Certified copies of the priority documents have been received.	eived in Application No	
3. Copies of the certified copies of the priority documents happlication from the International Bureau (PCT Rule 1)	7.2(a)).	
*Certified copies not received:	·	
5. $\square$ Acknowledgement is made of a claim for domestic priority und	der 35 U.S.C. § 119(e) (to a provisional application).	
(a) $\square$ The translation of the foreign language provisional application	on has been received.	
6. $\square$ Acknowledgement is made of a claim for domestic priority und	der 35 U.S.C. §§ 120 and/or 121.	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this commoted below. Failure to timely comply will result in ABANDONMENT of the EXTENDABLE.		ts
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s)		Ξ
8. CORRECTED DRAWINGS must be submitted.		
(a) $\square$ including changes required by the Notice of Draftsperson's	Patent Drawing Review (PTO-948) attached	
1) hereto or 2) l to Paper No		
(b) $\square$ including changes required by the proposed drawing correct approved by the examiner.	ction filed, which has been	
(c) including changes required by the attached Examiner's Ame Paper No	endment/Comment or in the Office action of	
Identifying indicia such as the application number (see 37 CFR 1.84(c)) shoule each sheet. The drawings should be filed as a separate paper with a transmi		() of
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLO attached Examiner's comment regarding REQUIREMENT FOR TI		
Attachment(s)		
1 Notice of References Cited (PTO-892)	2 Notice of Informal Patent Application (PTO-152)	
3 Notice of Draftsperson's Patent Drawing Review (PTO-948)	4 X Interview Summary (PTO-413), Paper No.0403	•.
5 Information Disclosure Statement(s) (PTO-1449), Paper No(s).	6 X Examiner's Amendment/Comment	
7 La Examiner's Comment Regarding Requirement for Deposit of Biological Material	8 🗶 Examiner's Statement of Reasons for Allowance	
9 Other		

Application/Control Number: 09/669,301

Art Unit: 1634

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CAR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark Wilson on April 29, 2003.

The application has been amended as follows:

Non-elected claims 24-36 were canceled without prejudice towards further prosecution.

## Reasons for Allowance

2. The following is an examiner's statement of reasons for allowance:

The present invention is directed to a method comprising:

- a) obtaining at least a first soluble anti-nuclease antibody;
- b) obtaining at least a second soluble anti-nuclease antibody, wherein the first and the second soluble anti-nuclease antibodies bind to different nucleases;
  - c) obtaining a composition;
- d) admixing the anti-nuclease antibodies and the composition to form an admixture; wherein nucleases that may be present in the admixture are inhibited.

Although Lee et al. (Immunochemistry, (1972), Vol. 9, pages 210-213)) teaches a method comprising: a) obtaining at least a first soluble anti-nuclease antibody;

Application/Control Number: 09/669,301

Art Unit: 1634

c) obtaining a composition;

d) admixing the anti-nuclease antibody and the composition to form an admixture; wherein nucleases that may be present in the admixture are inhibited,

Lee et al does not teach the step (b) of obtaining at least a second soluble anti-nuclease antibody, wherein the first and the second soluble anti-nuclease antibodies bind to different nucleases.

In view of the absence of either teaching or suggestion of such a step (b) of obtaining at least a second soluble anti-nuclease antibody, wherein the first and the second soluble anti-nuclease antibodies bind to different nucleases, the present invention is novel and non-obvious.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119. The fax phone number for this

Application/Control Number: 09/669,301

Page 4

Art Unit: 1634

Group is (703) 746-4979. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237.

Arun Chakrabarti,

Patent Examiner,

April 29, 2003

GARY BENZION, PH. D

TECHNOLOGY CENTER 1600